Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application

项目摘要/摘要 作为国家癌症研究所(NCI)网络领先学术参与网站(NLAPS)，亨斯迈癌症 研究所(HCI)将为国家临床试验网络(NCTN)提供领导和强劲的收益 程序。我们之前作为NCI U10资助的NLAPS合作伙伴的成功证明，HCI NLAPS将 与SWOG、NRG肿瘤学和 肿瘤学临床试验联盟(联盟)NCTN小组，以及对临床的大量收益 整个NCTN的试验。Hi NLAPS执行团队在合作方面具有良好的资质和经验 团体研究。这位PI，David Gaffney，医学博士，是一名放射肿瘤学家，具有长期的领导历史和 参加NCTN活动。HCI的教职员工通过以下方式显著增加了NCTN计划的领导力 参与指导委员会、特别工作组和小组活动。在过去的四年里，三名人机界面教员 两名教职员工是国家首席调查员(研究主任)；两名教员是未决审判的国家首席调查员。 HCI对参与NCTN试验有着坚定的、既定的承诺。2017年，18%(96/532)的人机界面 NCTN试验获得了治疗收益，而且始终有50项NCTN治疗试验开放， 包括罕见疾病试验。2016年，所有HCI试验(n=67)中有27%是针对罕见癌症的。HCI看到了一个更大的 在过去的U10资助的赠款周期中，NCTN应计项目增长了50%以上：在赠款年度1-4从61个增加到96个。 在犹他大学的坚定承诺下，HCI有一个强有力的、不断增长的临床试验计划， 大量的慈善支持，最先进的设施，一家专门的肿瘤医院，和一个集中的 其临床研究企业的基础设施位于新的、连续的空间。我们中心还有独一无二的 对临床研究有价值的资产，包括农村和美洲原住民人口，NCI中心 以及犹他州人口数据库，这是人口- 基于家谱数据和全州的医疗和生命记录。 2015年，HCI晋升为综合癌症中心，获得了 ‘特别的’。设在犹他大学，这是西山区唯一的学术医疗中心，HCI 吸引了来自犹他州各地以及爱达荷州、内华达州、蒙大拿州和怀俄明州的癌症临床试验患者， 并为这类患者群体提供近乎排他性的服务。作为一个NLAP，HCI将是一个强大的、承诺的、 作为癌症中心的NCTN计划的持续合作伙伴，以专业知识、领导力和 主动应计项目。HCI将积极努力，确保NCTN的合作努力取得成功 根除癌症。

PROJECT SUMMARY/ABSTRACT As a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS), Huntsman Cancer Institute (HCI) will provide leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. As evidenced by our prior success as a NCI U10-funded NLAPS partner, the HCI NLAPS will contribute to the development and conduct of clinical trials in association with SWOG, NRG Oncology, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS executive team is well-qualified and experienced in cooperative group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and participation in NCTN activities. HCI's faculty adds significantly to the leadership of the NCTN program through participation on steering committees, task forces, and group activities. In the past four years, three HCI faculty were national principal investigators (PIs, study chairs); two faculty members are national PIs of pending trials. HCI has a strong, established commitment to participation in NCTN trials. In 2017, 18% (96/532) of HCI therapeutic accruals were made to NCTN trials and, consistently, >50 NCTN therapeutic trials are open, including rare disease trials. In 2016, 27% of all HCI trials (n=67) were for rare cancers. HCI saw a greater than 50% growth in NCTN accruals in the past U10-funded grant cycle: from 61 to 96 in grant years 1- 4. HCI has a vigorous and growing clinical trials program, with strong commitment from the University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and a centralized infrastructure for its clinical research enterprise housed in new, contiguous space. Our Center also has unique assets of value to clinical research, including rural and Native American populations, an NCI Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful interlinkage of population- based genealogical data and statewide medical and vital records. In 2015, HCI advanced to Comprehensive Cancer Center status, receiving an overall merit descriptor of `Exceptional'. Housed at the University of Utah, the only academic medical center in the Mountain West, HCI draws cancer clinical trial patients from across Utah, as well as from Idaho, Nevada, Montana, and Wyoming, and provides near-exclusive access to this patient population. As a NLAPS, HCI will be a strong, committed, and sustaining partner to the NCTN program as a cancer center characterized by expertise, leadership, and active accrual. HCI will work vigorously to ensure the success of the NCTN's cooperative endeavors to eradicate cancer.